ViiV Healthcare Company
$38.7M 65,891 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. reported $39,181,235.63 across General Payments, Research, and Ownership to 19,104 physicians and teaching hospitals across 36,687 transactions.
- $39.2M
- All-tracks total
- 36,687
- Transactions
- 19,104
- Recipients
- +$457.7K
- General Payments vs PY2023
Alnylam Pharmaceuticals Inc. reported $39,181,235.63 across all CMS Open Payments tracks (General + Research + Ownership) to 19,104 physicians and teaching hospitals in Program Year 2024 - ranking #58 of 1,925 reporting manufacturers (0.3% of the all-tracks industry total); General Payments alone were $6,505,436.41, averaging $2.1K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer alnylam-pharmaceuticals-inc Alnylam Pharmaceuticals Inc.
$39.2M · #58/1,925 · 0.3% industry · PY2024
- TOT $39.2M
- RANK #58
- SHARE 0.3%
- TXN 36,687
- RCP 19,104
- CAT 7
- GEN $6.5M
- ΔGEN +$457.7K
- TOP1 16.2%
- PY 2024
Volume peers
Nearest volume peer: ViiV Healthcare Company ($38.7M)
Alnylam Pharmaceuticals Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Alnylam Pharmaceuticals Inc.'s CMS-reported General Payments increased by $457.7K (+7.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ALNYLAM PHARMACEUTICALS INC.PY2023: ALNYLAM PHARMACEUTICALS INC.PY2024: Alnylam Pharmaceuticals Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $6,047,708.24
- PY2024
- $6,505,436.41
What the Data Shows for Alnylam Pharmaceuticals Inc.
Averaging $1.1K per transaction and $2.1K per recipient, Alnylam Pharmaceuticals Inc.'s Program Year 2024 total comes to $39,181,235.63 across 36,687 transactions and 19,104 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #58 of 1,925 companies, representing 0.3% of all industry payments reported nationwide for the year.
231 transactions worth $2.9M make "Consulting Fee" the top general-payment category in the 7-category breakdown below, 44.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 7 types of general payments, Alnylam Pharmaceuticals Inc.'s largest category was "Consulting Fee" at $2.9M - 44.8% of General Payments.
Alnylam Pharmaceuticals Inc. reports 7 general-payment categories - the top three are Consulting Fee (44.8%), Compensation for Services Other Than Consulting (34.0%), and Food and Beverage (8.5%). The remaining 4 categories make up 12.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Alnylam Pharmaceuticals Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $2.9M | 231 | 44.8% |
| Compensation for Services Other Than Consulting | $2.2M | 419 | 34.0% |
| Food and Beverage | $550.5K | 17,454 | 8.5% |
| Space Rental or Facility Fees | $421.6K | 104 | 6.5% |
| Travel and Lodging | $333.9K | 875 | 5.1% |
| Grant | $70.8K | 9 | 1.1% |
| Education | $598.48 | 12 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,782,449.53 (42.8%) of $6,505,436.41 in this company's General Payments records across 9,834 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Alnylam Pharmaceuticals Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Brigham And Womens Hospital
$1,050,759.48 across 6 reported transactions
- 2
Sushama Scalera
$488,887.50 across 10 reported transactions
- 3
Dennis Ausiello
$484,629.86 across 15 reported transactions
- 4
Margaret A Hamburg
$476,884.99 across 18 reported transactions
- 5
Arthur Decillis
$281,287.70 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Alnylam Pharmaceuticals Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Alnylam Pharmaceuticals Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Alnylam Pharmaceuticals Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Spinal Simplicity, LLC
$40.8M 4,988 recipients
Compare payment profiles
Boehringer Ingelheim International GmbH
$41.1M 2,203 recipients
Compare payment profiles
Exelixis Inc.
$37.1M 10,612 recipients
Compare payment profiles
Sanofi Pasteur Inc.
$42.5M 14,446 recipients
Compare payment profiles
Alexion Pharmaceuticals, Inc.
$34.7M 48,499 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.